Laila-Yasmin Mani

Dr. Laila-Yasmin Mani

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
FSFrancesco Scolari
Francesco Scolari
EDElisa Delbarba
Elisa Delbarba
DSDomenico Santoro
Domenico Santoro
LGLoreto Gesualdo
Loreto Gesualdo
APAntonello Pani
Antonello Pani
FIfor the RI-CYCLO Investigators
for the RI-CYCLO Investigators
Significance Statement: A cyclic regimen of corticosteroid and cyclophosphamide is the first-line therapy for membranous nephropathy. Rituximab is superior to conservative treatment and noninferior to cyclosporine in inducing remission; it also may have a more favorable safety profile compared with cyclic therapy, but a head-to-head comparison of rituximab versus cyclic therapy is lacking. Using a multisite design, the authors designed a pilot randomized trial to obtain estimates of the effects of the two therapies and to assess the recruitment potential of a noninferiority trial. They found rituximab and cyclophosphamide may have comparable effects on disease remission and a similar short-term safety profile. These data suggest that, although rituximab may be a valid alternative to cyclic therapy for patients with membranous nephropathy, a head-to-head pragmatic comparison would require a large, global, noninferiority trial. Background: A cyclic corticosteroid-cyclophosphamide regimen is the first-line therapy for membranous nephropathy. Compared with this regimen, rituximab therapy might have a more favorable safety profile, but a head-to-head comparison is lacking. Methods: We randomly assigned 74 adults with membranous nephropathy and proteinuria >3.5 g/d to rituximab (1 g) on days 1 and 15, or a 6-month cyclic regimen with corticosteroids alternated with cyclophosphamide every other month. The primary outcome was complete remission of proteinuria at 12 months. Other outcomes included determination of complete or partial remission at 24 months and occurrence of adverse events. Results: At 12 months, six of 37 patients (16%) randomized to rituximab and 12 of 37 patients (32%) randomized to the cyclic regimen experienced complete remission (odds ratio [OR], 0.4; 95% CI, 0.13 to 1.23); 23 of 37 (62%) receiving rituximab and 27 of 37 (73%) receiving the cyclic regimen had complete or partial remission (OR, 0.61; 95% CI, 0.23 to 1.63). At 24 months, the probabilities of complete and of complete or partial remission with rituximab were 0.42 (95% CI, 0.26 to 0.62) and 0.83 (95% CI, 0.65 to 0.95), respectively, and 0.43 (95% CI, 0.28 to 0.61) and 0.82 (95% CI, 0.68 to 0.93), respectively, with the cyclic regimen. Serious adverse events occurred in 19% of patients receiving rituximab and in 14% receiving the cyclic regimen. Conclusions: This pilot trial found no signal of more benefit or less harm associated with rituximab versus a cyclic corticosteroid-cyclophosphamide regimen in the treatment of membranous nephropathy. A head-to-head, pragmatic comparison of the cyclic regimen versus rituximab may require a global noninferiority trial. Clinical Trial registry name and registration number: Rituximab versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (RI-CYCLO), NCT03018535

19 June 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KKKrzysztof Kiryluk
Krzysztof Kiryluk
ESElena Sanchez-Rodriguez
Elena Sanchez-Rodriguez
XZXu-Jie Zhou
Xu-Jie Zhou
FZFrancesca Zanoni
Francesca Zanoni
LLLili Liu
Lili Liu
AGAli G. Gharavi
Ali G. Gharavi

18 September 2023 in Clinical Kidney Journal
Verified
Journal Article
Open access
PDF file
GHGaye Hafez
Gaye Hafez
JMJolanta Malyszko
Jolanta Malyszko
AGAleksandra Golenia
Aleksandra Golenia
AKAleksandra Klimkowicz-Mrowiec
Aleksandra Klimkowicz-Mrowiec
AFAna Carina Ferreira
Ana Carina Ferreira
Sophie LiabeufSophie Liabeuf
Sophie Liabeuf
There is growing evidence that chronic kidney disease (CKD) is an independent risk factor for cognitive impairment, especially due to vascular damage, blood–brain barrier disruption and uremic toxins. Given the presence of multiple comorbidities, the medication regimen of CKD patients often becomes very complex. Several medications such as psychotropic agents, drugs with anticholinergic properties, GABAergic drugs, opioids, corticosteroids, antibiotics and others have been linked to negative effects on cognition. These drugs are frequently included in the treatment regimen of CKD patients. The first review of this series described how CKD could represent a risk factor for adverse drug reactions affecting the central nervous system. This second review will describe some of the most common medications associated with cognitive impairment (in the general population and in CKD) and describe their effects.

23 July 2014 in Hemodialysis International
Verified
Journal Article
Closed access
PDF file
LMLaila-Yasmin Mani
Laila-Yasmin Mani
SKSébastien Kissling
Sébastien Kissling
DVDragana Viceic
Dragana Viceic
BVBruno Vogt
Bruno Vogt
MBMichel Burnier
Michel Burnier
DRDelphine Renard
Delphine Renard

30 March 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
DSDaniel Sidler
Daniel Sidler
ABAlexander Born
Alexander Born
SSSimeon Schietzel
Simeon Schietzel
MHMichael P. Horn
Michael P. Horn
DADaniel Aeberli
Daniel Aeberli
MMMatthias B Moor
Matthias B Moor
Background The majority of patients with B-cell-depleting therapies show compromised vaccination-induced immune responses. Herein, we report on the trajectories of anti-SARS-CoV-2 immune responses in patients of the RituxiVac study compared with healthy volunteers and investigate the immunogenicity of a third vaccination in previously humoral non-responding patients. Methods We investigated the humoral and cell-mediated immune response after SARS-CoV-2 messanger RNA vaccination in patients with a history with anti-CD20 therapies. Coprimary outcomes were antispike and SARS-CoV-2-stimulated interferon-γ concentrations in vaccine responders 4.3 months (median; IQR: 3.6–4.8 months) after first evaluation, and humoral and cell-mediated immunity (CMI) after a third vaccine dose in previous humoral non-responders. Immunity decay rates were compared using analysis of covariance in linear regression. Results 5.6 months (IQR: 5.1–6.7) after the second vaccination, we detected antispike IgG in 88% (29/33) and CMI in 44% (14/32) of patients with a humoral response after two-dose vaccination compared with 92% (24/26) healthy volunteers with antispike IgG and 69% (11/16) with CMI 6.8 months after the second vaccination (IQR: 6.0–7.1). Decay rates of antibody concentrations were comparable between patients and controls (p=0.70). In two-dose non-responders, a third SARS-CoV-2 vaccine elicited humoral responses in 19% (6/32) and CMI in 32% (10/31) participants. Conclusion This study reveals comparable immunity decay rates between patients with anti-CD20 treatments and healthy volunteers, but inefficient humoral or CMI after a third SARS-CoV-2 vaccine in most two-dose humoral non-responders calling for individually tailored vaccination strategies in this population. Trial registration number NCT04877496; ClinicalTrials.gov number.

12 February 2016 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
MSMaryam Seif
Maryam Seif
LMLaila-Yasmin Mani
Laila-Yasmin Mani
HLHuanxiang Lu
Huanxiang Lu
CBChris Boesch
Chris Boesch
MRMauricio Reyes
Mauricio Reyes
PVPeter Vermathen
Peter Vermathen
Purpose To investigate if image registration of diffusion tensor imaging (DTI) allows omitting respiratory triggering for both transplanted and native kidneys Materials and Methods Nine kidney transplant recipients and eight healthy volunteers underwent renal DTI on a 3T scanner with and without respiratory triggering. DTI images were registered using a multimodal nonrigid registration algorithm. Apparent diffusion coefficient (ADC), the contribution of perfusion (FP), and the fractional anisotropy (FA) were determined. Relative root mean square errors (RMSE) of the fitting and the standard deviations of the derived parameters within the regions of interest (SDROI) were evaluated as quality criteria. Results Registration significantly reduced RMSE in all DTI‐derived parameters of triggered and nontriggered measurements in cortex and medulla of both transplanted and native kidneys (P < 0.05 for all). In addition, SDROI values were lower with registration for all 16 parameters in transplanted kidneys (14 of 16 SDROI values were significantly reduced, P < 0.04) and for 15 of 16 parameters in native kidneys (9 of 16 SDROI values were significantly reduced, P < 0.05). Comparing triggered versus nontriggered DTI in transplanted kidneys revealed no significant difference for RMSE (P > 0.14) and for SDROI (P > 0.13) of all parameters. In contrast, in native kidneys relative RMSE from triggered scans were significantly lower than those from nontriggered scans (P < 0.02), while SDROI was slightly higher in triggered compared to nontriggered measurements in 15 out of 16 comparisons (significantly for two, P < 0.05). Conclusion Registration improves the quality of DTI in native and transplanted kidneys. Diffusion parameters in renal allografts can be measured without respiratory triggering. In native kidneys, respiratory triggering appears advantageous. J. Magn. Reson. Imaging 2016;44:327–334.